Agency: Cordis | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-07-2014 | Award Amount: 30.95M | Year: 2015
Over 12 million people in Europe suffer from neurodegenerative diseases (ND), yet treatments that prevent or stop the progression of neurodegeneration are still lacking. Tackling this grand challenge requires enhanced coordination of national efforts to accelerate discovery. Such synergies have been created among 28 countries in the pilot EU JPI on Neurodegenerative Disease Research (JPND). JPND has a long standing experience in collaborative action with 75 million of additional national funds being successfully mobilized between 2011 and 2014 to support transnational research programs. The JPND Research Strategy is now ripe for further enhancement in tight coordination with the EC through an ERA-Net Cofund instrument JPco-fuND with an unprecedented commitment of 30 million of national funds associated to a highly incentivizing EC top-up fund. Among the most burning questions, three priority topics have emerged through a consultative process between researchers and JPND members in order to unlock several major issues within ND research: the identification of genetic, epigenetic and environmental risk and protective factors, the development and maintenance of longitudinal cohorts, the creation of advanced experimental models. These are key questions of equal priority to increase understanding of ND mechanisms that will be addressed through a common joint transnational call allowing a significant acceleration of the execution of the JPND research strategy. Moreover, to expand the impact of JPco-fuND, JPND will continue to implement other actions without EU co-funding such as aligning national research strategies, making databases more accessible and interoperable, developing enabling capacities such as supportive infrastructure and platforms, capacity building, education and training. These actions are required in parallel to achieve the highest impact for the patients, their carers and for society as whole and address this grand challenge in the coming years.
Agency: Cordis | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-11-2015 | Award Amount: 20.88M | Year: 2016
The ERA-NET NEURON Cofund will coordinate and align European and international research funding programmes in the area of brain-related diseases and disorders of the nervous system. Key activity is the implementation of an EC co-funded joint transnational call for research proposals. The mission of NEURON is based on the fact that disorders of the brain are the major cause for impaired quality of life, and they are a heavy burden not only for patients, their families and carers, but also a socioeconomic problem for society. By improving collaboration and by implementing a variety of additional activities (such as further joint transnational calls and support of early-career scientists) NEURON Cofund will decrease fragmentation of research programmes and improve the funding situation for neuroscience researchers thereby strengthening the search for novel therapeutic approaches to fight brain disease; NEURON Cofund will also develop and provide concrete plans for (i) expanding data sharing, (ii) promoting common data elements for the establishment of patient registries, and (iii) involving stakeholders and relevant existing initiatives such as patient organizations. The aforementioned challenges will be addressed in a network of 22 funding organizations across 14 European Member and Associated States and Third countries.
Azana J.,INRS - Institute National de la Recherche Scientifique
IEEE Photonics Journal | Year: 2010
This paper reviews recent work on the design, experimental implementation, and application of two fundamental all-optical analog signal processing functionalities, namely, photonic temporal differentiation and photonic temporal integration, using customized grating devices directly written in optical fibers. © 2009 IEEE. Source
Gauthier M.A.,INRS - Institute National de la Recherche Scientifique
Antioxidants and Redox Signaling | Year: 2014
The objective of most modern drug delivery strategies is to maximize the effectiveness of drug molecules at diseased tissue and to minimize their effects in healthy ones. This is most often achieved using (bio-)synthetic carrier systems that release the drug at the target location. One emerging strategy to achieve this is to destabilize carriers and release therapeutics using natural redox gradients in the body or associated with disease. The body, however, is composed of numerous microenvironments whose redox homeostasis, as well as its dysregulation due to disease, is complex. The original article and authoritative reviews that constitute this Forum discuss some of the particular redox features associated with diseases and present an overview of how, chemically, redox-responsive drug delivery carriers can be designed to respond to these opportunities. © Copyright 2014, Mary Ann Liebert, Inc. Source
Sylvestre M.,INRS - Institute National de la Recherche Scientifique
Environmental Microbiology | Year: 2013
Summary: The fate of polychlorinated biphenyls (PCBs) in soil is driven by a combination of interacting biological processes. Several investigations have brought evidence that the rhizosphere provides a remarkable ecological niche to enhance the PCB degradation process by rhizobacteria. The bacterial oxidative enzymes involved in PCB degradation have been investigated extensively and novel engineered enzymes exhibiting enhanced catalytic activities toward more persistent PCBs have been described. Furthermore, recent studies suggest that approaches involving processes based on plant-microbe associations are very promising to remediate PCB-contaminated sites. In this review emphasis will be placed on the current state of knowledge regarding the strategies that are proposed to engineer the enzymes of the PCB-degrading bacterial oxidative pathway and to design PCB-degrading plant-microbe systems to remediate PCB-contaminated soil. Copyright © 2012 Society for Applied Microbiology and Blackwell Publishing Ltd. Source